Want to see NAUT full AI Analyst Report?
NAUT Stock Chart & Stats
$0.88
-$0.08(-4.52%)
At close: 4:00 PM EDT
$0.88
-$0.08(-4.52%)
Day’s Range― - ―
52-Week Range$0.65 - $4.31
Previous CloseN/A
Volume624.38K
Average Volume (3M)820.38K
Market Cap
$115.15M
Enterprise Value$181.53
Total Cash (Recent Filing)$84.03M
Total Debt (Recent Filing)$27.82M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 03, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding127,255,226
10 Day Avg. Volume652,366
30 Day Avg. Volume820,380
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Proteoform Technology DifferentiationThe platform’s differentiated resolution and reproducibility could support defensible adoption in research and drug discovery. External collaborations and demonstrated biological insights strengthen technical validation, although commercial scale still must be proven.
Focused Proteoform Commercialization RoadmapConcentrating resources on proteoforms gives the company a clearer product and assay strategy than pursuing broadscale applications equally. A staged roadmap may improve execution focus and create multiple future commercialization opportunities.
Cost Discipline And Available LiquidityLower operating expenses and a stated cash runway provide time to advance the product roadmap before substantial commercialization. This financial flexibility can support development milestones, though continued losses mean the runway is not self-sustaining.
Bears Say
Minimal Revenue And Persistent LossesThe company remains pre-commercial or only early commercial, with revenue far below the cost base and no evidence of operating scale. Persistent large losses indicate that profitability depends on successful future launches and substantial customer adoption.
Cash Burn And Future Financing RequirementCash consumption remains substantial despite reported cost improvements, and management anticipates raising capital before mid-2027. New debt or equity could constrain flexibility or dilute existing holders if commercialization milestones take longer.
Broadscale Execution And Market-access RiskDelaying broadscale availability removes a potentially important near-term application and shifts dependence toward the narrower proteoform roadmap. Extended probe, modeling and architecture work increases uncertainty around timing, scope and eventual customer demand.
Nautilus Biotechnolgy News
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $0.65 and its highest was $4.31 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Nautilus Biotechnolgy’s market cap is $115.15M.
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Nov 03, 2026 which is in 56 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Jul 28, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.025.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -0.14.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 127,255,226 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went down -27.711%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Currently, no hedge funds are holding shares in NAUT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nautilus Biotechnolgy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (354.55% Upside)
$4.00 (354.55% Upside)
Blogger Sentiment
Bearish
NAUT Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 960.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nautilus Biotechnolgy
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
NAUT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong technical and scientific momentum around proteoform capabilities (unique resolution, reproducible assays, collaborations, and a clear proteoform commercialization roadmap) and demonstrates cost discipline. However, meaningful commercial revenues remain nascent, the broadscale application is delayed and requires long-duration work, the commercial organization is small, and the company expects to need additional capital before mid-2027. The positives on technology, customer enthusiasm, and a staged product launch are balanced by execution and financing risks tied to broadscale delays and limited near-term revenue.View all NAUT earnings summariesNAUT Stock 12 Month Forecast
Average Price Target
$4.00
▲(354.55% Upside)
Technical Analysis
Ownership Overview
45.20% Insiders
2.79% Mutual Funds
24.90% Other Institutional Investors
23.41% Public Companies and
Individual Investors